Related Experiment Video
Updated: Jun 26, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected,
S E Erdman1, V P Rao, T Poutahidis
1Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. serdman@mit.edu
Abstract:
Recombinase-activating gene-2-deficient (Rag2(-/-)) mice lacking functional lymphocytes provide a useful model of chronic inflammatory bowel disease-emulating events in human colon cancer. Infection of Rag2(-/-) mice with Helicobacter hepaticus led to accumulation of macrophages and neutrophils in the colon, a process temporally related to up-regulation of tissue inducible nitric oxide synthase (iNOS) expression at the site of infection and increased nitric oxide (NO) production, as evidenced by urinary excretion of nitrate. Progressive development of increasingly severe inflammation, hyperplasia, dysplasia, and cancer accompanied these changes. Concurrent administration of an iNOS inhibitor prevented NO production and abrogated epithelial pathology and inhibited the onset of cancer. The presence of Gr-1(+) neutrophils and elevated tumor necrosis factor-alpha (TNF-alpha) expression in colon were required for increased iNOS expression and cancer, whereas interleukin-10 (IL-10) down-regulated TNF-alpha and iNOS expression and suppressed cancer. Anti-inflammatory CD4(+) regulatory lymphocytes also down-regulated iNOS and reduced cancer formation. Collectively, these results confirm essential roles for inflammation, increased TNF-alpha expression, and elevated NO production in colon carcinogenesis.
Insights
Recombinase-activating gene-2-deficient mice infected with Helicobacter hepaticus developed colon cancer. Inhibiting inducible nitric oxide synthase (iNOS) prevented cancer, highlighting NO
Area of Science:
- Immunology
- Gastroenterology
- Oncology
Background:
- Recombinase-activating gene-2-deficient (Rag2(-/-)) mice are a model for chronic inflammatory bowel disease and colon cancer.
- Helicobacter hepaticus infection in Rag2(-/-) mice mimics human colon cancer development.
Purpose of the Study:
- To investigate the role of inducible nitric oxide synthase (iNOS) and associated inflammatory mediators in Helicobacter hepaticus-induced colon carcinogenesis in Rag2(-/-) mice.
- To explore the impact of neutrophils, tumor necrosis factor-alpha (TNF-alpha), interleukin-10 (IL-10), and regulatory T cells on iNOS expression and cancer development.
Main Methods:
- Infection of Rag2(-/-) mice with Helicobacter hepaticus.
- Assessment of inflammatory cell accumulation (macrophages, neutrophils).
- Measurement of inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production (urinary nitrate excretion).
- Evaluation of epithelial pathology (hyperplasia, dysplasia) and cancer incidence.
- Administration of an iNOS inhibitor.
- Analysis of Gr-1(+) neutrophils, TNF-alpha, IL-10, and CD4(+) regulatory T cell involvement.
Main Results:
- Helicobacter hepaticus infection induced macrophage and neutrophil accumulation, increased iNOS expression, and elevated NO production in the colon.
- Progressive inflammation, hyperplasia, dysplasia, and cancer developed in infected mice.
- iNOS inhibition abrogated NO production, prevented epithelial pathology, and inhibited cancer onset.
- Neutrophils and TNF-alpha were required for increased iNOS expression and cancer.
- IL-10 and CD4(+) regulatory T cells suppressed TNF-alpha and iNOS expression, reducing cancer formation.
Conclusions:
- Inflammation, elevated TNF-alpha, and increased NO production are critical drivers of colon carcinogenesis in this model.
- Targeting iNOS and modulating inflammatory pathways holds therapeutic potential for colon cancer prevention.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease
Gastritis II: Pathophysiology

